Dennis H. Giesing's most recent trade in Immunome Inc was a trade of 50,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 8, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | Dennis H. Giesing | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | Dennis H. Giesing | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | Dennis H. Giesing | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 16,609 | 16,609 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | Dennis H. Giesing | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) |